Innoviva (INVA)
(Delayed Data from NSDQ)
$18.87 USD
+0.32 (1.73%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $18.88 +0.01 (0.05%) 5:24 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INVA 18.87 +0.32(1.73%)
Will INVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INVA
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
Is Innoviva (INVA) Stock Undervalued Right Now?
INVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
Other News for INVA
Top 5 Value Stocks For A Big Tech Pullback (SA Quant)
FHLC: Healthcare Dashboard For July
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
Innoviva: Potentially Overvalued
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs